BioNTech to Develop the First mRNA-Based Vaccine for Malaria Prevention

BioNTech said it aims to develop the first messenger RNA-based malaria vaccine and hopes to launch a clinical trial by the end of next year.

The German drugmaker said it is working on the project with the World Health Organization and the Africa Centers for Disease Control and Prevention as part of a new initiative to boost the vaccine manufacturing capacity of low- and middle-income African countries and eradicate malaria worldwide.

BioNTech also announced plans to launch a clinical trial of a tuberculosis vaccine candidate in 2022.